The mTOR signaling pathway is dysregulated in∼ 50% of all human malignancies and is a
major cancer drug target. Although rapamycin analogs (rapalogs) have shown clinical …

Mechanistic target of rapamycin (mTOR) is the kinase subunit of two structurally and
functionally distinct large multiprotein complexes, referred to as mTOR complex 1 (mTORC1) …

The mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, acts as a
“master switch” for cellular anabolic and catabolic processes, regulating the rate of cell …

The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular
metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling …

Recent years have observed significant advances in our understanding of how the
serine/threonine kinase target of rapamycin (TOR) controls key cellular processes such as …

The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation,
acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 …

The mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine
kinase and the founding member of a signaling pathway that regulates many fundamental …

A flurry of reports indicates that we are entering a new phase in the development of
mammalian target of rapamycin (mTOR)–based therapies for oncology. Here, we summarize …

Mechanistic target of rapamycin (mTOR) is a conserved threonine and serine protein kinase
that was identified more than two decades ago as the target of immunosuppressive drug …

Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth
and metabolism in response to nutrients, growth factors and cellular energy levels, and it is …